United Therapeutics Corporation (UTHR), Wednesday announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to the company's investigational miroliverELAP for treatment of acute liver failure.
Developed by Miromatrix Medical Inc., a subsidiary of United Therapeutics, miroliverELAP comprises of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to ALF patients.
Early this year, the company announced positive results from its phase 1 study of miroliverELAP. However, the full study findings will be published in the second half of 2026.
"Receiving this designation from the FDA highlights both the critical unmet need we are addressing and the promising potential of miroliverELAP as a novel therapeutic option," said Jeff Ross, Ph.D., President of Miromatrix.
In the pre-market hours, UTHR is trading at $573.96, up 1.46 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.